Burden of comorbidities among patients with atrial fibrillation
- PMID: 23090783
- DOI: 10.1177/1753944712464101
Burden of comorbidities among patients with atrial fibrillation
Abstract
Objective: This study examined comorbidity prevalence and general medication use among individuals with atrial fibrillation in the United States to convey a more comprehensive picture of their total disease burden.
Methods: This was a retrospective, observational evaluation of responses to the 2009 wave of the annual Internet-based National Health and Wellness survey, which collects health data including epidemiologic data and information on medical treatment from a representative nationwide sample of adults in the United States. Responses were assessed to determine three measures of comorbidity: mean number of comorbidities, CHADS2 score reflecting stroke risk (0-6 points; low risk: 0; moderate risk: 1; high risk: ≥ 2), and scores on the Charlson Comorbidity Index, which is a measure of general comorbidity reflecting presence of a wide range of comorbidities.
Results: Of the overall sample, 1297 participants reported having been diagnosed with atrial fibrillation. Almost all (98%) of the predominantly male (65.1%) and older (≥ 65 years of age, 65.7%) population with atrial fibrillation had at least one additional comorbidity, and 90% had cardiovascular comorbidities. On the Charlson Comorbidity Index, 44.9% of the respondents had scores of 1-2 and 20.5% had scores of 3 or higher. High risk for stroke, demonstrated by a CHADS2 score of at least 2, was present in 45% and moderate risk (CHADS2 score 1) in 36%. Of the respondents with atrial fibrillation, 71% reported current use of medication to manage the condition, but only 48% of individuals at high risk for stroke reported use of anticoagulation therapy. Of those who reported having common risk factors for stroke, the majority reported receiving prescription therapy for these conditions.
Conclusions: The health burden carried by patients often extends far beyond atrial fibrillation. Physicians should carefully consider comorbidities and concomitant medications when managing patients with atrial fibrillation.
Similar articles
-
Dyspepsia and disease burden among patients with atrial fibrillation.Crit Pathw Cardiol. 2012 Mar;11(1):14-9. doi: 10.1097/HPC.0b013e318246fae8. Crit Pathw Cardiol. 2012. PMID: 22337216
-
Prevalence of stroke and the need for thromboprophylaxis in young patients with atrial fibrillation: a cohort study.J Cardiovasc Med (Hagerstown). 2014 Mar;15(3):189-93. doi: 10.2459/JCM.0b013e3283654c4b. J Cardiovasc Med (Hagerstown). 2014. PMID: 24625564
-
The value of the CHA2DS2-VASc score for refining stroke risk stratification in patients with atrial fibrillation with a CHADS2 score 0-1: a nationwide cohort study.Thromb Haemost. 2012 Jun;107(6):1172-9. doi: 10.1160/TH12-03-0175. Epub 2012 Apr 3. Thromb Haemost. 2012. PMID: 22473219
-
[Atrial fibrillation, comorbidities and new anticoagulants].Geriatr Psychol Neuropsychiatr Vieil. 2013 Dec;11(1 Suppl):10-6. doi: 10.1684/pnv.2013.0447. Geriatr Psychol Neuropsychiatr Vieil. 2013. PMID: 24463059 Review. French.
-
Treatment of atrial fibrillation.Br Med Bull. 2008;88(1):75-94. doi: 10.1093/bmb/ldn046. Epub 2008 Dec 5. Br Med Bull. 2008. PMID: 19059992 Review.
Cited by
-
Impact of multimorbidity and polypharmacy on the management of patients with atrial fibrillation: insights from the BALKAN-AF survey.Ann Med. 2021 Dec;53(1):17-25. doi: 10.1080/07853890.2020.1799241. Epub 2020 Aug 4. Ann Med. 2021. PMID: 32700579 Free PMC article.
-
Impact of comorbid conditions on disease-specific quality of life in older men and women with atrial fibrillation.Qual Life Res. 2020 Dec;29(12):3285-3296. doi: 10.1007/s11136-020-02578-3. Epub 2020 Jul 11. Qual Life Res. 2020. PMID: 32656722 Free PMC article.
-
Multimorbidity, physical frailty, and self-rated health in older patients with atrial fibrillation.BMC Geriatr. 2020 Sep 11;20(1):343. doi: 10.1186/s12877-020-01755-w. BMC Geriatr. 2020. PMID: 32917137 Free PMC article.
-
Atrial fibrillation and comorbidities: Clinical characteristics and antithrombotic treatment in GLORIA-AF.PLoS One. 2021 Apr 14;16(4):e0249524. doi: 10.1371/journal.pone.0249524. eCollection 2021. PLoS One. 2021. PMID: 33852611 Free PMC article. Clinical Trial.
-
Impact of Integrated Care Management on Clinical Outcomes in Atrial Fibrillation Patients: A Report From the FANTASIIA Registry.Front Cardiovasc Med. 2022 May 2;9:856222. doi: 10.3389/fcvm.2022.856222. eCollection 2022. Front Cardiovasc Med. 2022. PMID: 35586656 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical